These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36796751)

  • 1. ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
    Yuan Y; Zhang X; Wu Y; Lian P; Cao X; Xu Y
    Neuroscience; 2023 Jul; 523():61-79. PubMed ID: 36796751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
    Huang YT; Chen YW; Lin TY; Chen JC
    Neurobiol Dis; 2024 Apr; 193():106452. PubMed ID: 38401650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
    Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
    Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mGlu
    Tan Y; Cheng C; Zheng C; Zeng W; Yang X; Xu Y; Zhang Z; Ma Z; Xu Y; Cao X
    Pharmacol Biochem Behav; 2023 Oct; 231():173637. PubMed ID: 37714223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
    Nishijima H; Mori F; Kimura T; Miki Y; Kinoshita I; Nakamura T; Kon T; Suzuki C; Wakabayashi K; Tomiyama M
    Neurosci Res; 2022 May; 178():93-97. PubMed ID: 35150767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Booth S; Ramadan A; Zhang D; Lu L; Kirouac G; Jackson MF; Anderson C; Ko JH
    Mov Disord; 2021 Apr; 36(4):938-947. PubMed ID: 33135810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
    Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
    Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
    BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
    Gardoni F; Morari M; Kulisevsky J; Brugnoli A; Novello S; Pisanò CA; Caccia C; Mellone M; Melloni E; Padoani G; Sosti V; Vailati S; Keywood C
    J Pharmacol Exp Ther; 2018 Dec; 367(3):442-451. PubMed ID: 30291173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.